Tuberculosis biomarkers discovery: Developments, needs, and challenges

The Lancet Infectious Diseases

Volumn 13, Issue 4, 2013, Pages 362-372

  Wallis, Robert S ^a,b,c   Kim, Peter ^d   Cole, Stewart ^e   Hanna, Debra ^f   Andrade, Bruno B ^d   Maeurer, Markus ^g   Schito, Marco ^d   Zumla, Alimuddin ^h,i  

^a PFIZER INC   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e EPFL   (Switzerland)

^f Critical Path Institute   (United States)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR7; ETHAMBUTOL; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 18; ISONIAZID; LIPOARABINOMANNAN; MICRORNA; PROTEIN BCL 2; PYRAZINAMIDE; RIFAMPICIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

BACTERICIDAL ACTIVITY; BIOASSAY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PANCREAS ISLET BETA CELL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; RECURRENT DISEASE; REVIEW; SPUTUM CULTURE; T LYMPHOCYTE; TUBERCULOSIS;

ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DNA, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-18; LIPOPOLYSACCHARIDES; METABOLOME; MICRORNAS; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RECURRENCE; REPRODUCIBILITY OF RESULTS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84875595918     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70034-3     Document Type: Review

References (130)

1. Global tuberculosis report 2012. Report number WHO/HTM/TB/2012.6 2012, WHO, World Health Organization, Geneva, (accessed 5 Dec, 2012). http://www.who.int/tb/publications/global_report/gtbr12_main.pdf.
2. TB: a global emergency. Report number WF 205 94 TB C.2 1994, WHO, World Health Organization, Geneva, (accessed Sept 22, 2011). http://whqlibdoc.who.int/hq/1994/WHO_TB_94.177.pdf.
3. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers working group.
4. Wallis RS Sustainable tuberculosis drug development. Clin Infect Dis 2013, 56:106-113.
5. Mitchison DA Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]. Am Rev Respir Dis 1993, 147:1062-1063.
6. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. Eur Respir J 2012, 39:1269-1271.
7. Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med 2011, 184:1076-1084.
8. Darban-Sarokhalil D, Imani Fooladi AA, Maleknejad P, et al. Comparison of smear microscopy, culture, and real-time PCR for quantitative detection of Mycobacterium tuberculosis in clinical respiratory specimens. Scand J Infect Dis 2012, published online Oct 31. 10.3109/00365548.2012.727465.
9. Honeyborne I, McHugh TD, Phillips PP, et al. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J Clin Microbiol 2011, 49:3905-3911.
10. Li L, Mahan CS, Palaci M, et al. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to anti-tuberculosis therapy. J Clin Microbiol 2010, 48:46-51.
11. Desjardin LE, Perkins M, Wolski K, et al. Measurement of sputum M tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 1999, 160:203-210.
12. Epstein MD, Schluger NW, Davidow AL, Bonk S, Rom WN, Hanna B Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998, 113:379-386.
13. Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010, 14:560-570.
14. Bark CM, Okwera A, Joloba ML, et al. Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures. Tuberculosis (Edinb) 2011, 91:257-259.
15. Weiner M, Prihoda TJ, Burman W, et al. Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol 2010, 48:4370-4376.
16. Wallis RS, Perkins M, Phillips M, et al. Induction of the antigen 85 complex of M. tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis. J Infect Dis 1998, 178:1115-1121.
17. Wallis RS, Perkins M, Phillips M, et al. Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 2000, 161:1076-1080.
18. Wallis RS, Phillips M, Johnson JL, et al. Inhibition of INH-induced expression of M. tuberculosis antigen 85 in sputum: a potential surrogate marker in TB chemotherapy trials. Antimicrob Agents Chemother 2001, 45:1302-1304.
19. Brindle R, Odhiambo J, Mitchison DA Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001, 1:2.
20. Dietze R, Hadad DJ, Peloquin C, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008, 178:1180-1185.
21. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC 207 in pulmonary tuberculosis. Antimicrob Agents Chemother 2008, 52:2831-2835.
22. Davies GR, Brindle R, Khoo SH, Aarons LJ Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother 2006, 50:3154-3156.
23. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, et al. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis 2012, 16:1180-1185.
24. Goodridge A, Cueva C, Lahiff M, et al. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. Tuberculosis (Edinb) 2012, 92:243-247.
25. Wood R, Racow K, Bekker LG, et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis 2012, published online Feb 27. 10.1186/1471-2334-12-47.
26. Cannas A, Goletti D, Girardi E, et al. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2008, 12:146-151.
27. Azzurri A, Kanaujia GV, Sow OY, et al. Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea. Int J Immunopathol Pharmacol 2006, 19:199-208.
28. Veenstra H, Baumann R, Carroll NM, et al. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol 2006, 145:252-260.
29. Syhre M, Chambers ST The scent of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2008, 88:317-323.
30. Phillips M, Cataneo RN, Condos R, et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb) 2007, 87:44-52.
31. Adetifa IM, Ota MO, Jeffries DJ, et al. Interferon gamma ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am J Respir Crit Care Med 2012, 187:439-445.
32. Higuchi K, Harada N, Mori T Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008, 13:468-472.
33. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006, 174:831-839.
34. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004, 38:754-756.
35. Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002, 40:704-706.
36. Higuchi K, Harada N, Fukazawa K, Mori T Relationship between whole-blood interferon-γ responses and the risk of active tuberculosis. Tuberculosis (Edinb) 2008, 88:244-248.
37. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008, 177:1164-1170.
38. Wallis RS, Palaci M, Vinhas S, et al. A whole blood bactericidal assay for tuberculosis. J Infect Dis 2001, 183:1300-1303.
39. Janulionis E, Sofer C, Song HY, Wallis RS Lack of activity of oral clofazimine against intracellular M. tuberculosis in whole blood culture. Antimicrob Agents Chemother 2004, 48:3133-3135.
40. Wallis RS, Vinhas SA, Johnson JL, et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 2003, 187:270-278.
41. Immanuel C, Rajeswari R, Rahman F Serial evaluation of serum neopterin in HIV seronegative patients treated for tuberculosis. Int J Tuberc Lung Dis 2001, 5:185-190.
42. Hosp M, Elliott AM, Raynes JG, et al. Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis. Lung 1997, 175:265-275.
43. Demir T, Yalcinoz C, Keskinel I, Demiroz F, Yildirim N sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 2002, 6:155-159.
44. Chan CH, Lai CK, Leung JC, Ho AS, Lai KN Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy. Eur Respir J 1995, 8:70-73.
45. Brahmbhatt S, Black GF, Carroll NM, et al. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol 2006, 146:243-252.
46. Ribeiro-Rodrigues R, Resende CT, Johnson JL, et al. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol 2002, 9:818-823.
47. Lawn SD, Wiktor S, Coulibaly D, Ackah AN, Lal RB Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg 2001, 95:41-42.
48. Bajaj G, Rattan A, Ahmad P Prognostic value of 'C' reactive protein in tuberculosis. Indian Pediatr 1989, 26:1010-1013.
49. Scott GM, Murphy PG, Gemidjioglu ME Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein. J Infect 1990, 21:61-69.
50. Eugen-Olsen J, Gustafson P, Sidenius N, et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002, 6:686-692.
51. Djoba Siawaya JF, Bapela NB, et al. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J Infect 2008, 56:340-347.
52. Cheon SH, Kampmann B, Hise AG, et al. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol 2002, 9:901-907.
53. Hoft DF, Worku S, Kampmann B, et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective mycobacterium tuberculosis immunity. J Infect Dis 2002, 186:1448-1457.
54. Fletcher HA, Scriba TJ, Tanner R, et al. Evaluating mycobacterial growth inhibition assays (MGIA) in TB vaccine studies. Global Forum TB Vaccines 2013 (in press); 3 (abstract).
55. Kampmann B, Gaora PO, Snewin VA, Gares MP, Young DB, Levin M Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. J Infect Dis 2000, 182:895-901.
56. Kampmann B, Tena GN, Mazazi S, Young D, Eley B, Levin M A novel human in vitro system to evaluate antimycobacterial vaccines. Infect Immun 2004, 72:6401-6417.
57. Tena GN, Young DB, Eley B, et al. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus, and its relationship to T cell function. J Infect Dis 2003, 187:1544-1551.
58. Kampmann B, Tena-Coki GN, Nicol M, Levin M, Eley B Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS 2006, 20:1011-1018.
59. Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007, 176:208-213.
60. Sutherland JS, Hill PC, Adetifa IM, et al. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS One 2011, 6:e25230.
61. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011, 183:88-95.
62. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:937-973.
63. Mistry R, Cliff JM, Clayton C, et al. Gene expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 2007, 195:357-365.
64. Hirsch CS, Toossi Z, Vanham G, et al. Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis 1999, 179:945-953.
65. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006, 368:1012-1021.
66. Weiner J, Parida SK, Maertzdorf J, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 2012, 7:e40221.
67. Wang C, Yang S, Sun G, et al. Comparative miRNA expression profiles in individuals with latent and active tuberculosis. PLoS One 2011, 6:e25832.
68. Hellyer TJ, Desjardin LE, Teixeira L, Perkins MD, Cave MD, Eisenach KD Detection of viable Mycobacterium tuberculosis by reverse transcriptase-strand displacement amplification of mRNA. J Clin Microbiol 1999, 37:518-523.
69. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354.
70. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375:1920-1937.
71. Wallis RS, Doherty TM, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2009, 9:162-172.
72. Wallis RS, Wang C, Doherty TM, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2010, 10:68-69.
73. Lee M, Lee J, Carroll M, et al. Linezolid for the treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012, 367:1508-1518.
74. Wallis RS, Nacy C Early bactericidal activity of new drug regimens for tuberculosis. Lancet 2013, 381:111-112.
75. Wallis RS, Jakubiec W, Kumar V, et al. Biomarker assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011, 55:567-574.
76. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010, 181:174-180.
77. Weyer K, Mirzayev F, Migliori G, et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert(R)MTB/RIF. Eur Respir J 2012, published online Nov 22. 10.1183/09031936.00157212.
78. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, published online March 24. http://dx.doi.org/10.1016/S1473-3099(13)70008-2.
79. Peter JG, Theron G, Muchinga TE, Govender U, Dheda K The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS One 2012, 7:e39966.
80. Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012, 40:1211-1220.
81. Mukundan H, Kumar S, Price DN, et al. Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensor. Tuberculosis (Edinb) 2012, 92:407-416.
82. Mikusova K, Slayden RA, Besra GS, Brennan PJ Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 1995, 39:2484-2489.
83. Via LE, Schimel D, Weiner DM, et al. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [(1)(8)F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother 2012, 56:4391-4402.
84. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011, 12:15-22.
85. John SH, Kenneth J, Gandhe AS Host biomarkers of clinical relevance in tuberculosis: review of gene and protein expression studies. Biomarkers 2012, 17:1-8.
86. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 2011, 184:1153-1163.
87. Bloom CI, Graham CM, Berry MP, et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 2012, 7:e46191.
88. Cliff JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013, 207:18-29.
89. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:45-55.
90. Diel R, Loddenkemper R, Nienhaus A Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012, 142:63-75.
91. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37:88-99.
92. Yamada G, Shijubo N, Shigehara K, Okamura H, Kurimoto M, Abe S Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. Am J Respir Crit Care Med 2000, 161:1786-1789.
93. Hirsch CS, Toossi Z, Johnson JL, et al. Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis 2001, 183:779-788.
94. Jones-Lopez EC, Ellner JJ, Whalen CC Subclinical tuberculosis: a new entity?. Clin Infect Dis 2005, 41:1069-1070.
95. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005, 40:1500-1507.
96. Achkar JM, Jenny-Avital ER Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis 2011, 204(suppl 4):S1179-S1186.
97. Kall MM, Coyne KM, Garrett NJ, et al. Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study. BMC Infect Dis 2012, 12:107.
98. Alling DW, Bosworth EB The after-history of pulmonary tuberculosis. VI. The first fifteen years following diagnosis. Am Rev Respir Dis 1960, 81:839-849.
99. Singh KK, Dong Y, Belisle JT, Harder J, Arora VK, Laal S Antigens of Mycobacterium tuberculosis recognized by antibodies during incipient, subclinical tuberculosis. Clin Diagn Lab Immunol 2005, 12:354-358.
100. Raqib R, Kamal SM, Rahman MJ, et al. Use of antibodies in lymphocyte secretions for detection of subclinical tuberculosis infection in asymptomatic contacts. Clin Diagn Lab Immunol 2004, 11:1022-1027.
101. Talat N, Shahid F, Dawood G, Hussain R Dynamic changes in biomarker profiles associated with clinical and subclinical tuberculosis in a high transmission setting: a four-year follow-up study. Scand J Immunol 2009, 69:537-546.
102. Kunnath-Velayudhan S, Davidow AL, Wang HY, et al. Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients. J Infect Dis 2012, 206:697-705.
103. Cooper AM Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
104. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
105. Qiu Y, Chen J, Liao H, et al. Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions. PLoS Pathog 2012, 8:e1002984.
106. Henao-Temayo M, Irwin SM, Shang S, Ordway D, Orme I T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis. Tuberculosis (Edinb) 2011, 91:308-313.
107. Kleinsteuber K, Heesch K, Schattling S, et al. SOCS3 promotes interleukin-17 expression of human T cells. Blood 2012, 120:4374-4382.
108. Le Bourhis L, Martin E, Peguillet I, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 2010, 11:701-708.
109. Gold MC, Cerri S, Smyk-Pearson S, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 2010, 8:e1000407.
110. Brennan MJ, Thole J Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012, 92(suppl 1):S6-13.
111. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns. Am J Respir Crit Care Med 2010, 182:1079.
112. Cheng SH, Walker L, Poole J, et al. Demonstration of increased anti-mycobacterial activity in peripheral blood monocytes after BCG vaccination in British school children. Clin Exp Immunol 1988, 74:20-25.
113. Hoft DF, Blazevic A, Abate G, et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198:1491-1501.
114. Saliu O, Sofer C, Stein DS, Schwander SK, Wallis RS Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194:486-492.
115. Wallis RS, Vinhas S, Janulionis E Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. Tuberculosis (Edinb) 2009, 89:221-224.
116. Floto RA, MacAry PA, Boname JM, et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 2006, 314:454-458.
117. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Bull World Health Organ 1972, 46:371-385.
118. Sepulveda RL, Parcha C, Sorensen RU Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuber Lung Dis 1992, 73:372-377.
119. Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366:1290-1295.
120. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996, 348:17-24. Karonga Prevention Trial Group.
121. Cunha SS, Alexander N, Barreto ML, et al. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. PLoS Negl Trop Dis 2008, 2:e167.
122. Leung CC, Tam CM, Chan SL, Chan-Yeung M, Chan CK, Chang KC Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int J Tuberc Lung Dis 2001, 5:717-723.
123. Batz H-G, Cooke GS Towards lab-free tuberculosis diagnosis Reid SD for Médecins Sans Frontières, (accessed Dec 8, 2012). http://www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/TB_Report_TowardsLabFreeTBDX_2011_ENG.pdf.
124. Pellin D, Miotto P, Ambrosi A, Cirillo DM, Di SC A genome-wide identification analysis of small regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and conservation analysis. PLoS One 2012, 7:e32723.
125. Nemeth J, Winkler HM, Zwick RH, et al. Peripheral T cell cytokine responses for diagnosis of active tuberculosis. PLoS One 2012, 7:e35290.
126. Nemeth J, Winkler HM, Boeck L, et al. Specific cytokine patterns of pulmonary tuberculosis in Central Africa. Clin Immunol 2011, 138:50-59.
127. Harari A, Rozot V, Enders FB, et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011, 17:372-376.
128. Giri PK, Kruh NA, Dobos KM, Schorey JS Proteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis-infected and culture filtrate protein-treated macrophages. Proteomics 2010, 10:3190-3202.
129. Nahid P, Saukkonen J, Mac Kenzie WR, et al. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 2011, 184:972-979.
130. Research in latent tuberculosis infection (LTBI) in the setting of HIV co-infection (R01). DC: US Department of Health and Human Services, December 2012 US Department of Health and Human Services, (accessed Mar 4, 2013). http://grants1.nih.gov/grants/guide/pa-files/PAR-13-061.html.